Insights
New antiplatelet ticagrelor offers potential benefits for acute coronary syndrome (ACS) patients. This review examines its efficacy and bleeding risk compared to standard dual antiplatelet therapy.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Current National Institute for Clinical Excellence (NICE) guidelines recommend dual antiplatelet therapy (aspirin plus clopidogrel or prasugrel) for acute coronary syndrome (ACS).
- Dual antiplatelet therapy increases bleeding risk compared to aspirin monotherapy.
- Ticagrelor is a novel oral antiplatelet agent approved for ACS management.
Purpose of the Study:
- To review the role of ticagrelor in managing patients with acute coronary syndrome (ACS).
- To evaluate if ticagrelor offers improved efficacy or reduced bleeding complications compared to existing therapies.
Main Methods:
- Review of current clinical guidelines and pharmacological data.
- Analysis of clinical trial outcomes regarding efficacy and safety of ticagrelor in ACS.
Main Results:
- Ticagrelor is indicated for ACS patients, including those managed medically, undergoing percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG).
- The review assesses ticagrelor's comparative effectiveness and safety profile against standard antiplatelet regimens.
Conclusions:
- Ticagrelor represents a new therapeutic option for ACS management.
- Further evaluation is needed to establish its definitive advantages in efficacy and bleeding risk reduction within the current treatment landscape.
Abstract:
Current guidelines from the National Institute for Clinical Excellence (NICE) recommend antiplatelet therapy comprising aspirin plus either clopidogrel or prasugrel for patients with acute coronary syndrome (ACS). However, such dual therapy increases the likelihood of bleeding compared to that with aspirin alone. Ticagrelor (Brilique - Astra-Zeneca) is a new oral antiplatelet drug recently licensed in the UK (since publication of the NICE guidelines) for use with aspirin in patients with ACS, including those managed medically or undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Here we review the place of ticagrelor in the management of people with ACS, and whether it offers advantages over standard therapy in terms of greater efficacy or lower likelihood of bleeding complications.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Acute Coronary Syndrome V: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care